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ABSTRACT 
Performing well designed and ethical trials in pediatric inflammatory bowel diseases (IBD) is a 
priority to support optimal therapy and to reduce the unacceptable long lag between adult and 
pediatric drug approval. Recently, clinical trials in children have been incorporating placebo 
arms into their protocols under conditions that created controversy. Therefore, four organizations 
(ESPGHAN, ECCO, the Canadian Children IBD Network and the global pediatric IBD network 
(PIBDnet)) jointly provide a statement on the role of placebo in pediatric IBD trials. Consensus 
was achieved by 94/100 (94%) voting committees' members that placebo should only be used if 
there is genuine equipoise between the active treatment and placebo. For example, this may be 
considered in trials of drugs with new mechanisms of action without existing adult data, 
especially when proven effective alternatives do not exist outside the trial. Placebo may also be 
used in situations where it is an ‘add-on” to an effective therapy or to evaluate exit-strategies of 
maintenance therapy after long-term deep remission. However, it has been agreed that no child 
enrolled in a trial should receive a known inferior treatment both within and outside the trial. 
This also includes withholding therapy in children who show clinical response after a short 
induction therapy. Given the similarity between pediatric and adult IBD in regards to 
pathophysiology and response to treatments, drugs generally cannot be considered being in 
genuine equipoise with placebo if it has proven efficacy in adults. Continued collaboration of all 
stakeholders is needed to facilitate drug development and evaluation in pediatric IBD. 
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ECCO 
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Introduction 
After approval of new therapies for adults with inflammatory bowel diseases (IBD) there is a 
long delay before pediatric trials are started, and an even longer delay until such therapies 
receive pediatric approval (Figure 1). While children and adolescents with IBD may have more 
aggressive and extensive disease than adults, it is generally accepted that the pathophysiology 
and response to treatment are similar in the two groups (excluding very early onset IBD). This 
has led pediatric gastroenterologists to widely apply “off-label” use of therapies approved for 
adult use.  
 
Recently, regulators united to discuss common approaches toward a much needed harmonized 
drug development process in pediatric IBD (1, 2). Among others, they concluded that partial 
extrapolation of efficacy from informative adult studies may be appropriate, allowing for small 
pediatric trials that are underpowered to demonstrate efficacy. It was also suggested  that a 
placebo arm should generally be included in pediatric IBD maintenance trials )2( . The regulators 
stated that the risks of placebo are minimal if an early escape strategy is embedded within the 
protocol. This led to an international controversy among the stakeholders with ongoing 
constructive discussions with regulators. 
    
This position paper from ESPGHAN, ECCO, the Canadian Children IBD Network and the 
global Pediatric IBD network (PIBDnet) is written following intensive face-to-face discussions 
and multiple email exchange within the groups and its governing boards and an open dialogue 
initiated by the United States Food and Drug Administration (FDA) and the European Medicines 
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Agency (EMA). It is supported by 94 (94%) of the 100 pediatric IBD experts who voted, from 
the relevant governing committees of the four supporting organizations (see Appendix for a list 
of supporting members, http://links.lww.com/MPG/A573). Two Canadian bioethicists were 
involved in the discussions as well as the ethics committee of ESPGHAN.   
 
Where is the right place for placebo in pediatric IBD trials?  
According to the Helsinki declaration and the EU GCP Directive (2001/20/EC), no child enrolled 
in a trial should receive a known inferior treatment (3). Similarly, the 2014 Canadian Tri-Council 
Policy Statement (TCPS) on Ethical Conduct for Research Involving Humans cautions that 
where there is an established therapy, use of a placebo may deprive participants of needed 
therapy (http://www.pre.ethics.gc.ca/pdf/eng/tcps2-2014/TCPS_2_FINAL_Web.pdf). Thus, the 
use of placebo-controlled trials in children is generally considered adequate only if there is 
clinical equipoise, both against the active comparator within the trial and against standard of care 
outside of the trial. Equipoise is defined as "a genuine uncertainty on the part of the expert 
community about the therapeutic benefits of each arm". This may be the case when a new 
therapy with a novel mechanism of action without established data in adults is to be evaluated in 
children, especially when no other alternatives with proven efficacy exist outside the trial. 
Placebo may also be used in situations where it is an "add-on" to an effective therapy, while the 
effective therapy is continued. In IBD children with longstanding deep remission with proven 
mucosal healing, discontinuation of effective treatment may be clinically reasonable and thus 
randomization to placebo or a drug treatment may be considered. However, this has not been the 
design of phase-3 pediatric trials performed for regulatory purposes.  
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Concerns arising from the design of current trials  
Concerns have arisen in view of the study design of a recently launched clinical trial to examine 
the role of a biologic agent in pediatric UC. In this phase-3 trial, children with moderate to 
severe disease responding to a short open label induction phase are randomized to three 
maintenance groups, including placebo. The apparent justification for including placebo is that it 
would be unclear whether the biologic drug is effective in children. However, the drug has 
proven to be effective in large placebo-controlled trials in adults with IBD and is already 
approved for use in adults for that indication. This drug has been used extensively "off-label" for 
several years in children, and the clinical experience of many pediatric IBD experts supports the 
conclusion that the drug is effective also in children. Therefore, the question whether equipoise 
exists in pediatric trials is markedly influenced by how much the medical community accepts 
extrapolation of results from prior adult IBD placebo-controlled trials to the pediatric patient. If 
one accepts sufficient extrapolation, then once a drug has been proven to be effective in adults 
and is being used "off label" in children, study design must take in account the fact that offering 
a placebo may be inappropriate as it does not meet the requirements of standard of care and non-
inferior treatment.  
 
Practically, the medical community accepts extrapolation on an everyday practice. Pediatric IBD 
experts are using therapies approved for adult IBD in their pediatric patients years before 
pediatric data are available (Figure 1), since the evidence supports similarity between pediatric 
and adult IBD in regards to genetics, pathophysiology, immunology and response to treatments. 
In fact, there has not been hitherto any single precedent where an IBD drug proved to be 
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effective in adults but not in children (e.g. steroids, budesonide, 5-ASA, azathioprine, 
methotrexate, cyclosporin, infliximab, adalimumab, thalidomide, beclomethasone diproprionate 
etc; Figure 2). Therefore, the adequacy for using placebo following just a few weeks of active 
therapy in pediatric patients with a severe and treatable disease has been questioned, and many 
pediatric gastroenterologists resist participating in such a trial that would expose some of their 
patients to withdrawal of an apparently effective therapy. Members of this group are aware that 
other studies are currently planned with a similar design using a placebo control for drugs which 
have been proven effective in prior adult placebo controlled trials.  
 
ESPGHAN, ECCO, the Canadian Children IBD Network, and the global PIBDnet take the view 
that one should not include a placebo arm in pediatric IBD trials if this leads to withholding 
therapy that can be reasonably assumed to be beneficial, based on the results of trials from 
adults, strengthened by preceding clinical experience in pediatric patients. It is questionable 
whether continuing existing treatment, such as thiopurines, can be considered effective treatment 
since the drug has failed previously, as evident from the inclusion of the child with active disease 
to a trial. 
 
It should be emphasized, however, that the group recommends extrapolation of drug efficacy 
only for IBD and each disease must be considered individually. It should also be emphasized that 
although prior adult IBD data predict effectiveness also in children, it does not exempt the 
scientific community and pharmaceutical companies to conduct randomized-controlled studies in 
children to understand dosing, safety and the best way how to use the drug in children. We 
propose considering pediatric trial designs in which the comparator would be an active arm of an 
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established standard treatment, and to also perform studies focusing on pharmacokinetics, 
pharmacodynamics (PK/PD) and safety. We also propose focusing more attention on young 
children (2-11 years of age) who currently are mostly excluded from drug trials, given the open 
questions on appropriate drug dosage in this population.  
  
With regards to maintenance therapy, an early trial by Markowitz et al. on the effect of 
thiopurines in an inception cohort of children with CD, which was performed when maintenance 
treatment in newly diagnosed children was not considered standard of care, showed clear 
superiority of maintenance treatment over placebo, after an open label induction period with 
steroids (4). Since then, many studies with different drugs, in various populations and conditions 
confirmed that exacerbation would occur unless children are kept on maintenance treatment, 
especially following a moderate-severe exacerbation that is the typical prerequisite inclusion into 
biologics trials. The more extensive nature of pediatric IBD as compared to adults, the risk of 
lasting growth impairment, and the fact that children depend on the decision of their caregivers, 
mandates that children who had moderate-severe IBD are not left without available effective 
treatment. Caregivers must make all choices for the best interest of their child and cannot consent 
to participation of their child in a drug trial only for the benefit of future patients, as altruistic 
adults may elect to do for themselves. Withholding treatment represents a clear deviation from 
accepted clinical practice and standard of care, as recommended in current pediatric guidelines of 
managing UC and CD (5, 6).  
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It has been proposed that children with IBD randomized to placebo may benefit, since the 
placebo induced clinical remission has been reported as high as 20% in UC and CD (7, 8). 
However, objective measures of mucosal inflammation are now considered more appropriate as 
primary outcomes (9). When using complete mucosal healing as the study outcome, placebo 
remission rate is very low or even zero, as previously reported (10, 11).  
   
Drug withdrawal after clinical response and later reintroduction 
Regulators currently foresee study design in children as an open-label induction phase, followed 
by drug withdrawal in responders with randomization to active drug and placebo and potential 
later reintroduction of the active drug, if needed (2). However, response does not equal remission 
and children with moderate-severe disease at trial entry who are considered responders may still 
have active disease at time of randomization. Standard clinical practice would not lead to 
interrupting drug treatment in children with residual active disease. In fact, standard clinical 
practice mandates continuation of long term maintenance active treatment in all children after 
moderate-severe attack even if they achieve complete remission after a short induction therapy 
(5, 6). 
  
If one would randomize only children who achieved complete clinical remission, a practical 
difficulty arises. Assuming a clinical remission rate of ~30% after a short induction phase, as in 
prior pediatric biologics trials (12-14), one would need to enroll >1000 children into the 
induction phase to achieve an adequately powered study during the maintenance phase with a 
placebo and two arms with different dosages, which is not really feasible. Enrolling 200 children 
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to the induction phase would yield a power of <25% in the maintenance phase under the same 
assumptions. Indeed, the regulators concluded with respect to studies of IBD in children: "In the 
setting of partial extrapolation, clinical studies do not need to be fully powered for efficacy" (2). 
If trials are not powered to demonstrate efficacy, the need of placebo becomes even more 
questionable.   
 
A further concern with respect to currently proposed study designs is the potential disadvantage 
of temporary withdrawal of biologics with regards to later efficacy and safety. The STORI trial 
followed 115 adults with CD treated with both infliximab and immunomodulator for at least 1 
year, who were in steroid-free clinical remission for at least 6 months (15) and in whom 
infliximab treatment was then stopped. Most patients with signs of mucosal inflammation (as 
usually evident 6-8 weeks after starting induction treatment) flared shortly after discontinuation 
of the drug. As many as 12% of those re-treated with infliximab did not respond any more. 
Similarly, in other studies the average non-response to re-introduction of biologics after a 
temporary drug withdrawal has been 10-15% and most studies included selected cohorts of 
patients with long standing remission with concomitant immunomodulators. Thus, this figure 
likely represents a conservative non-response estimate (15-22). A meta-analysis of 7 studies 
showed that a temporary biologic drug withdrawal is associated with significantly higher rate of 
serious infusion reactions (23). Therefore, study designs based on drug withdrawal in patients 
responding to induction therapy and the possibility of later re-introduction may put participating 
children at a significant disadvantage, and hence remain highly controversial.   
 
Conclusions 
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Performing timely, well designed and ethically sound clinical drug trials in pediatric IBD is an 
important priority since at present too many medications are prescribed as “off label” in children. 
However, the development and assessment of drugs for pediatric IBD will not be facilitated if 
trial designs are considered inappropriate or non-enrollable by the medical community and/or 
patients. Placebo-controlled trials continue to be the gold standard for drug evaluation, but they 
can only be used in pediatrics if there is clinical equipoise, i.e. a genuine uncertainty shared by 
the medical community about the therapeutic benefits of each arm. Further discussion and close 
collaboration of all stakeholders, including medical-scientific societies, patient organizations, 
regulatory agencies and the pharmaceutical industry is needed to facilitate optimal care for 
children and adolescents with IBD.    
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LEGENDS TO FIGURES 
Figure 1: Years interval from approval of biologics in adults to approval in children  
 
Footnote: Top two indications have not received pediatric approval yet and pediatric trials are 
still ongoing; the light gray arrows illustrate the anticipated future years to approval. 
 
Figure 2: Comparison of adult and pediatric biologics trial results 
 
Footnote: For the sake of fair comparisons between pediatric and adult trials, REACH data 
reflect complete ITT (including primary non responders) and the IMAgINE and CHARM trials 
include only those who were infliximab naïve 
 
Supplemental Data: Appendix 
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